Results 71 to 80 of about 53,515 (238)
Ipilimumab-induced colitis on FDG PET/CT.
A 52-year-old woman with metastatic melanoma was treated with ipilimumab. After 2 cycles of treatment, she developed watery diarrhea, sweats, and chills.
Carvajal, Richard D +3 more
core +1 more source
Background A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically.
Caroline Robert +17 more
doaj +1 more source
Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy [PDF]
BACKGROUND: Ipilimumab+nivolumab (IPINIVO) can induce durable responses in advanced melanoma, but many patients experience progression at some point. It is currently unknown to what extent these patients benefit from IPINIVO rechallenge.
van der Veldt, A A M +52 more
core +1 more source
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris +4 more
wiley +1 more source
Ipilimumab, -omics, and head and neck cancers—update in 2025
Immunotherapy employing immune checkpoint inhibitors (ICIs) represents a pivotal approach for the management of recurrent and metastatic head and neck cancers (HNCs).
Robert Kucharski +7 more
doaj +1 more source
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault +3 more
wiley +1 more source
Introduction: Immunotherapies, including checkpoint inhibitors (CIs) such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) inhibitors, are revolutionizing the treatment of advanced melanoma.
Elizabeth S Mearns +6 more
doaj +1 more source
ABSTRACT Purpose Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated.
Mischa de Ridder +24 more
wiley +1 more source
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma [PDF]
Background Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma.
Thomas, Luc +23 more
core +2 more sources
Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem +20 more
wiley +1 more source

